[
  {
    "ts": "2026-02-25T12:11:35+00:00",
    "headline": "2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question",
    "summary": "The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.",
    "url": "https://finance.yahoo.com/news/2-nasdaq-100-stocks-worth-121135536.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "8751ad6c-f62b-339c-aa2f-64b0996efd00",
      "content": {
        "id": "8751ad6c-f62b-339c-aa2f-64b0996efd00",
        "contentType": "STORY",
        "title": "2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question",
        "description": "",
        "summary": "The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.",
        "pubDate": "2026-02-25T12:11:35Z",
        "displayTime": "2026-02-25T12:11:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/064ceaf2c6ba56fea4ffc6cc66d81aa4",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "NFLX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SxbPsQheAOuZ4LtBHYmkGg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/064ceaf2c6ba56fea4ffc6cc66d81aa4.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZRwHGy3zquxbnpg7qbFRsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/064ceaf2c6ba56fea4ffc6cc66d81aa4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-nasdaq-100-stocks-worth-121135536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-nasdaq-100-stocks-worth-121135536.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "NFLX"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T12:52:14+00:00",
    "headline": "Is Amgen Stock Outperforming the Dow?",
    "summary": "Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.",
    "url": "https://www.barchart.com/story/news/412335/is-amgen-stock-outperforming-the-dow",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "e82fbedc-9a99-3335-8558-6b86b108ae13",
      "content": {
        "id": "e82fbedc-9a99-3335-8558-6b86b108ae13",
        "contentType": "STORY",
        "title": "Is Amgen Stock Outperforming the Dow?",
        "description": "",
        "summary": "Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.",
        "pubDate": "2026-02-25T12:52:14Z",
        "displayTime": "2026-02-25T12:52:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/8b7be3f0b351490d96e4455556c30311",
          "originalWidth": 1254,
          "originalHeight": 836,
          "caption": "AMGEN Inc_ HQ sign- by JHVEPhoto via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1LBMviTbDVNwXx9R8t5UCw--~B/aD04MzY7dz0xMjU0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/8b7be3f0b351490d96e4455556c30311.cf.webp",
              "width": 1254,
              "height": 836,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZmpZ8Shu_HmFX0VOOluYzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/8b7be3f0b351490d96e4455556c30311.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/412335/is-amgen-stock-outperforming-the-dow",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-stock-outperforming-dow-125214444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "$DOWI"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T18:44:00+00:00",
    "headline": "Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy",
    "summary": "FOSTER CITY, Calif., February 25, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The",
    "url": "https://finance.yahoo.com/news/gilead-single-tablet-regimen-bictegravir-184400830.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "32910183-0a4f-3e14-8400-32766d43edb2",
      "content": {
        "id": "32910183-0a4f-3e14-8400-32766d43edb2",
        "contentType": "STORY",
        "title": "Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy",
        "description": "",
        "summary": "FOSTER CITY, Calif., February 25, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The",
        "pubDate": "2026-02-25T18:44:00Z",
        "displayTime": "2026-02-25T18:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c6473a840af0851372ca14eb2fa58dd0",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CJiHwlKSA0jiJkcX.8mDPg--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/c6473a840af0851372ca14eb2fa58dd0.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2M2mZwYxMQQXMsDOd9mXIQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6473a840af0851372ca14eb2fa58dd0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-single-tablet-regimen-bictegravir-184400830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-single-tablet-regimen-bictegravir-184400830.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T17:38:00+00:00",
    "headline": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
    "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
    "url": "https://www.barrons.com/articles/merck-hiv-drug-islatravir-doravirine-wall-street-9c8bdd68?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b6cace0e-a7a8-3015-9ce0-f8d15ff509ac",
      "content": {
        "id": "b6cace0e-a7a8-3015-9ce0-f8d15ff509ac",
        "contentType": "STORY",
        "title": "Merck’s New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.",
        "description": "",
        "summary": "Merck’s two-drug HIV regimen matched Gilead’s blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda’s patent cliff.",
        "pubDate": "2026-02-25T17:38:00Z",
        "displayTime": "2026-02-25T17:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b6cace0e-a7a8-3015-9ce0-f8d15ff509ac/merck%E2%80%99s-new-hiv-drug-shows.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90d15ef755712d958b31f4c7a338b648",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u4_cQJsJU8sh6V5CFZLpiQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90d15ef755712d958b31f4c7a338b648.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XLgqNEUXTraAktmiPS9siQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90d15ef755712d958b31f4c7a338b648.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/merck-hiv-drug-islatravir-doravirine-wall-street-9c8bdd68?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]